Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.72 |
| ▸ | BRD4 | O60885 | 4/20 | 0.72 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.72 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.59 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559327 | 0.93 | PLK1 (0.72) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1559834 | 0.93 | PLK1 (0.72) | PLK1BRD4BRDTALKRAD52 | |
| SCHEMBL1560526 | 0.92 | PLK1 (0.70) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1559553 | 0.92 | PLK1 (0.86) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1559320 | 0.91 | PLK1 (0.85) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1560759 | 0.91 | PLK1 (0.69) | PLK1BRD4BRDTALKRAD52 | |
| SCHEMBL1559954 | 0.90 | PLK1 (0.77) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1675752 | 0.90 | PLK1 (0.83) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1560244 | 0.90 | PLK1 (0.83) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1675743 | 0.90 | PLK1 (0.82) | PLK1BRD4BRDTPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | PLK1 1/4885BRD4 903/4885BRDT 504/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | PLK1 1/4885BRD4 215/4885BRDT 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.